Real world use of targeted therapies in war veterans with kidney cancer

A retrospective study of the use of targeted therapies for advanced renal cell carcinoma (RCC) in war veterans in the USA reported poorer overall survival outcomes than those from clinical trials, as well as shorter treatment durations for first-line therapies with more frequent adverse events, dose reductions, and drug discontinuations. The study was published in […]

read more

Current role of mTOR inhibitors in metastatic kidney cancer

The following video interview with Dr Eric Jonasch, from the MD Anderson Cancer Center, Houston, Texas, describes the current role of mTOR inhibitors for the treatment of metastatic renal cell carcinoma (mRCC). Watch the video interview on Practice Update here

read more

Combination bevacizumab plus temsirolimus for second-line treatment of metastatic kidney cancer

A recent phase 2 study evaluated the combination of bevacizumab with temsirolimus in 39 patients with metastatic renal cell carcinoma (mRCC) after failure of first-line treatment with a vascular endothelial growth factor (VEGF) receptor inhibitor. After 6 months, 50.9% of patients were progression-free and median time to progression of the disease was 6.8 months. The […]

read more

Potential biomarkers may predict response to TKIs in metastatic kidney cancer

A recent study published in Clinical Cancer Research¬†and conducted in France has identified potential biological markers that are related to the formation of new blood vessels (angiogenesis) and regulated by the levels of oxygen reaching the tissues (hypoxia). These biomarkers have been found to be strong predictors of response, progression-free survival (PFS), and overall survival […]

read more

Axitinib for metastatic non-clear cell renal cell carcinoma

Results from a phase 2 clinical trial of axitinib (Inlyta) for patients with advanced non-clear cell renal cell carcinoma (RCC) who had failed prior treatment with temsirolimus (Torisel) are promising in terms of objective response rate (ORR) and progression-free survival (PFS).¬† Forty patients with metastatic or recurrent non-clear cell RCC who had failed treatment with […]

read more
Showing all 5 results
  TOP